EXTON, Pa.--(ChartTrends: Crohn’s Disease (US), report in which over 1000 moderate-to-severe or severe fulminant CD patient records were audited by treating gastroenterologists (GEs).)--BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that significantly more moderate-to-severe and severe fulminant Crohn’s disease (CD) patients who are treated with biologic agents have good-to-excellent ability to maintain function / perform activities of daily living and have a good-to-excellent overall quality of life compared to their non-biologic-treated equivalents. Furthermore, significantly more biologic-treated patients have seen an improvement in their disease over the past year than non-biologic-treated patients; however, more biologic-treated patients have missed more days of work due to their CD than their non-biologic-treated counterparts. The findings come from the recent,
ChartTrends: Crohn’s Disease (US) finds that the TNF-alpha inhibitor infliximab (Janssen Biotech/Merck/Mitsubishi Tanabe’s Remicade) captured the greatest first-line share and current market share of prescribed biologic agents for the treatment of CD; adalimumab (Abbott/Eisai’s Humira) is the second biologic agent for CD in regards to both first-line regimens and with current market share. Biogen Idec/Elan’s Tysabri and UCB’s Cimzia have a negligible impact on the CD market in regards to both first-line and current market shares.
Nearly half of the audited patients who are not currently and have never been treated with biologic agents are considered candidates for biologic therapy, indicating that there is still an unmet need with regards to currently available biologic regimens to treat moderate-to-severe and severe fulminant CD patients. The most common reason for non-biologic treatment is patient resistance, specifically, concerns for long-term safety and possible need for infusion.
For products in late-stage development for the treatment of CD, surveyed physicians are most familiar with and most interested in the interleukin (IL)-12/IL-23 inhibitor ustekinumab (Janssen Biotech/Janssen Cilag’s Stelara), however, the survey respondents reported that the oral chemokine receptor vercirnon (GlaxoSmithKline/ChemoCentryx’s Traficet-EN, formerly GSK-1605786) would bring the most value to their practice. Specifically, GEs report that they would consider switching or adding vercirnon in over one-third of their moderate-to-severe / severe fulminant patients, most commonly due to its oral formulation and unique mechanism of action.
ChartTrends: Crohn’s Disease (US) is a quantitative publication based on patient and laboratory data collected from over 1,000 moderate-to-severe and severe fulminant patient charts provided by 211 gastroenterologists in July 2012. All patients are pharmacologically treated for their CD and all brands represented. The reports provide insight into the factors that drive decisions to treat, brand selection of biologic therapies, patient characterizations and dosing trends among GEs. Through an in-depth review of specific patient charts, details such as product initiation, concomitant medications, and patient demographic variables help define patient types and identify therapy drivers. Patient profiles for the marketed biologics as well as products in late stage clinical development for CD are characterized.
About BioTrends Research Group, LLC
BioTrends Research Group, LLC provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.